Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale.
Center for Advanced Analytics.
Am J Clin Oncol. 2023 Sep 1;46(9):381-386. doi: 10.1097/COC.0000000000001017. Epub 2023 Jun 1.
Studies on frailty among pediatric patients with cancer are scarce. In this study, we sought to understand the effects of frailty on hospital outcomes in pediatric patients with cancer.
This retrospective study used data collected and stored in the Nationwide Inpatient Sample (NIS) between 2005 and 2014. These were hospitalized patients and hence represented the sickest group of patients. Frailty was measured using the frailty definition diagnostic indicator by Johns Hopkins Adjusted Clinical Groups.
Of 187,835 pediatric cancer hospitalizations included in this analysis, 11,497 (6.1%) were frail. The average hospitalization costs were $86,910 among frail and $40,358 for nonfrail patients. In propensity score matching analysis, the odds of in-hospital mortality (odds ratio, 2.08; 95% CI, 1.71-2.52) and length of stay (odds ratio, 3.76; 95% CI, 3.46-4.09) were significantly greater for frail patients. The findings of our study suggest that frailty is a crucial clinical factor to be considered when treating pediatric cancer patients in a hospital setting.
These findings highlight the need for further research on frailty-based risk stratification and individualized interventions that could improve outcomes in frail pediatric cancer patients. The adaptation and validation of a frailty-defining diagnostic tool in the pediatric population is a high priority in the field.
针对儿科癌症患者衰弱的研究较为匮乏。本研究旨在探讨衰弱对儿科癌症患者住院结局的影响。
本回顾性研究采用了 2005 年至 2014 年全美住院患者样本(NIS)中收集和存储的数据。这些患者住院治疗,代表了病情最严重的患者群体。采用约翰霍普金斯调整临床分组(Johns Hopkins Adjusted Clinical Groups)的衰弱定义诊断指标来衡量衰弱。
在本分析纳入的 187835 例儿科癌症住院患者中,有 11497 例(6.1%)为衰弱患者。衰弱患者的平均住院费用为 86910 美元,而非衰弱患者为 40358 美元。在倾向评分匹配分析中,衰弱患者的院内死亡率(比值比,2.08;95%置信区间,1.71-2.52)和住院时间(比值比,3.76;95%置信区间,3.46-4.09)的比值显著更高。本研究结果表明,在医院环境中治疗儿科癌症患者时,衰弱是一个需要考虑的重要临床因素。
这些发现强调了需要进一步研究基于衰弱的风险分层和个体化干预措施,以改善衰弱儿科癌症患者的结局。在该领域,制定适用于儿科人群的衰弱定义诊断工具并对其进行验证是当务之急。